Pharma Sector Q3 Earnings Preview: India Growth To Recover; U.S. To Remain Stable, Says ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
We expect pharma and healthcare companies under our coverage to report moderate growth during the quarter ended December 2020.
We expect easing of lockdown to support some recovery in the acute portfolio and injectable products.
U.S. revenues may witness marginal growth sequentially led by improvement in volumes of injectables, specialty portfolio and new launches. We estimate India business to grow in high single-digit as seen in secondary sales data.
Hospitals and diagnostic centres can report significant recovery QoQ with rise in occupancy levels and pathology test volumes.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.